



Regulatory Information

Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2011

(Pursuant to Article L.233-8 II of the French Commercial Code
and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Charenton-le-Pont, France (June 9, 2011 - 06:00 pm) – As of May 31, 2011, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:

| | May 31, 2011 |
|---|--------------|
| Shares outstanding | 212,677,324 |
| Exercisable voting rights | 223,308,510 |
| Total voting rights, based on all outstanding shares, including shares stripped of their voting rights* | 229,100,529 |

(*) Shares held by the Company, either in treasury or under the liquidity contract.

The world leader in ophthalmic optical products, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. The Company's mission is to enable everyone around the world to have good vision thanks to lenses that meet his or her unique vision requirements. Essilor allocates around 4% of annual revenues to research and development to continuously bring new, more effective products to market. Flagship brands include Varilux[®], Crizal[®], Definity[®], Xperio[®], Kodak[®] and Foster Grant[®]. Essilor also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of more than €3.9 billion in 2010 and employs 42,700 people. It operates 14 plants, 332 prescription laboratories and several research and development centers around the world and does business in around 100 countries.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in the CAC 40 index. Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Investor Relations and Financial Communications

Phone: +33 (0)1 49 77 42 16